BR0315568A - Formulações de depósito injetáveis - Google Patents

Formulações de depósito injetáveis

Info

Publication number
BR0315568A
BR0315568A BR0315568-4A BR0315568A BR0315568A BR 0315568 A BR0315568 A BR 0315568A BR 0315568 A BR0315568 A BR 0315568A BR 0315568 A BR0315568 A BR 0315568A
Authority
BR
Brazil
Prior art keywords
injectable depot
depot formulations
injectable
viscous
formulations
Prior art date
Application number
BR0315568-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0315568A publication Critical patent/BR0315568A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
BR0315568-4A 2002-10-25 2003-10-13 Formulações de depósito injetáveis BR0315568A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42147302P 2002-10-25 2002-10-25
PCT/IB2003/004576 WO2004037289A2 (en) 2002-10-25 2003-10-13 Novel injectable depot formulations

Publications (1)

Publication Number Publication Date
BR0315568A true BR0315568A (pt) 2005-08-23

Family

ID=32176718

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315568-4A BR0315568A (pt) 2002-10-25 2003-10-13 Formulações de depósito injetáveis

Country Status (20)

Country Link
US (1) US20040138237A1 (enExample)
EP (1) EP1575616A2 (enExample)
JP (1) JP2006514923A (enExample)
KR (1) KR20050055781A (enExample)
CN (1) CN1849110A (enExample)
AR (1) AR041722A1 (enExample)
AU (1) AU2003267788A1 (enExample)
BR (1) BR0315568A (enExample)
CA (1) CA2503076A1 (enExample)
MX (1) MXPA05002561A (enExample)
NL (1) NL1024590C2 (enExample)
NO (1) NO20052463L (enExample)
PA (1) PA8586201A1 (enExample)
PE (1) PE20040499A1 (enExample)
PL (1) PL377679A1 (enExample)
RU (1) RU2310450C2 (enExample)
TW (1) TW200423941A (enExample)
UY (1) UY28038A1 (enExample)
WO (1) WO2004037289A2 (enExample)
ZA (1) ZA200501921B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
DK2767292T3 (en) 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2603189A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
EP2067471B1 (en) * 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
EP2303229A1 (en) * 2008-06-16 2011-04-06 Debiopharm S.A. Concentrated oxaliplatin solution and its method of preparation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
FR3087107A1 (fr) 2018-10-15 2020-04-17 Avent Inc. Compositions, systèmes, kits et méthodes d'ablation neurale
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
IL145950A0 (en) * 1999-05-27 2002-07-25 Pfizer Prod Inc Ziprasidone suspension
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers

Also Published As

Publication number Publication date
MXPA05002561A (es) 2005-05-05
ZA200501921B (en) 2006-10-25
TW200423941A (en) 2004-11-16
NL1024590C2 (nl) 2005-05-23
US20040138237A1 (en) 2004-07-15
WO2004037289A3 (en) 2005-12-01
AU2003267788A1 (en) 2004-05-13
RU2005112207A (ru) 2005-09-10
PE20040499A1 (es) 2004-08-18
RU2310450C2 (ru) 2007-11-20
PL377679A1 (pl) 2006-02-06
KR20050055781A (ko) 2005-06-13
CA2503076A1 (en) 2004-05-06
NL1024590A1 (nl) 2004-04-27
AR041722A1 (es) 2005-05-26
UY28038A1 (es) 2004-05-31
NO20052463L (no) 2005-05-23
PA8586201A1 (es) 2004-09-16
JP2006514923A (ja) 2006-05-18
CN1849110A (zh) 2006-10-18
WO2004037289A2 (en) 2004-05-06
EP1575616A2 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
UY28038A1 (es) Nuevas formulaciones de liberación propongada inyectables
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0411361A (pt) composições oftálmicas contendo uma combinação sinérgica de dois polìmeros
BR0206984A (pt) Composições de depósito injetáveis e uso destas
SE0001899D0 (sv) New compounds
BRPI0413922A (pt) xantinas de 8-heteroarila substituìda
CA2150576A1 (fr) Compositions injectables a base de derives des taxanes
BR0211390A (pt) Tratamento de infecções da unha com no
PY0124152A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
CU20080082A7 (es) Diarilureas para el tratamiento de hipertensión pulmonar
BRPI0414858A (pt) métodos para preparação de corpos de óleo compreendendo ingredientes ativos
BRPI0411367A (pt) composições oftálmicas contendo uma combinação sinergìstica de três polìmeros
BR0315663A (pt) Formulações de depósito de agentes ativos de aril-heterocìclicos na forma de uma suspensão
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BRPI0417157A (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
FR2940611B1 (fr) Association de monosaccharides et d'adenosine et son utilisation en cosmetique
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
DE502005006070D1 (de) Kosmetische formulierung auf mikroemulsionsbasis enthaltend mandelsäure
EP1142573A4 (en) Antibacterial medicinal compositions
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0416716A (pt) composições de siloxano cìclico para a liberação de ingredientes ativos
ATE536166T1 (de) Emulsion

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.